New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 16, 2014
08:05 EDTCMRX, MRKChimerix regains worldwide rights to CMX157
Chimerix (CMRX) announced that it has regained the worldwide rights to CMX157, Chimerix's novel lipid acyclic nucleoside phosphonate, from Merck, known as MSD outside the United States and Canada. Following a routine pipeline portfolio assessment, Merck (MRK) made the decision to no longer pursue development of CMX157. The compound is currently being evaluated for future development opportunities; however, Chimerix has no present plans for allocation of current or future resources to the development of CMX157.
News For CMRX;MRK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
October 8, 2014
12:25 EDTCMRXOn The Fly: Midday Wrap
Subscribe for More Information
12:01 EDTCMRXChimerix plunges after first U.S. Ebola patient dies, levels to watch
The shares are down 11.5% to $29.38 following news that the first U.S. Ebola patient, Thomas Eric Duncan, has died. Duncan was being treated with the company's experimental Ebola drug, Brincidofovir. Based on current price, next support is at $27.62. Resistance is at $30.06 and then at $30.70.
11:55 EDTCMRXChimerix options active after Ebola patient taking experimental drug dies
Subscribe for More Information
11:52 EDTCMRXChimerix shares to be volatile as stock tracks Ebola news, says Piper Jaffray
Piper Jaffray noted the move lower in Chimerix following news that a patient in Texas that was being treated with its brincidofovir drug has died and said the stock will now be in a "much more volatile position" as its movements track news on the Ebola outbreak and treated patients. The firm believes the drug's usefulness in treating Ebola will need to be defined by more data and trials and that its established utility in other diseases provides value above the stock's current levels. Piper maintains its Overweight rating on shares of Chimerix.
11:22 EDTCMRXChimerix falls after Ebola patient taking experimental drug dies
Shares of Chimerix (CMRX) are moving lower after the Texas Health Presbyterian Hospital Dallas announced that Thomas Eric Duncan succumbed to Ebola. Duncan was being treated with Chimerix's experimental drug Brincidofovir. Shares of Chimerix dropped 9% following the news to $30.19. Other makers of experimental Ebola treatments include Tekmira (TKMR), Sarepta (SRPT) and BioCryst (BCRX).
11:17 EDTCMRXChimerix down 4% after Texas Ebola patient dies
Subscribe for More Information
11:14 EDTMRKMerck presents new MK-5172/MK-8742 clinical study data
Merck announced that new data from clinical studies of the company’s investigational, oral, once-daily, fixed-dose combination chronic hepatitis C treatment grazoprevir/elbasvir, or MK-5172/MK-8742, are scheduled to be presented at the 65th American Association for the Study of Liver Diseases Annual Meeting, also known as The Liver Meeting. The meeting is scheduled to take place from November 7-11. New data will also be presented for MK-3682, formerly IDX21437, as part of its purchase of Idenix Pharmaceuticals.
11:08 EDTMRKLeerink pharmaceuticals analyst holds an analyst/industry conference call
Analyst discusses IMPROVE-IT's regulatory and commercial implications for novel LDL-lowering therapies on an Analyst/Industry conference call to be held on October 9 at 2 pm.
10:55 EDTMRKLeerink pharmaceuticals analyst holds an analyst/industry conference call
Analysts discuss prospects for drugs that raise HDL cholesterol, effects of CETP mechanism, expectations for REVEAL data and the potential place for CETP inhibitors in a crowded hypersholesterolemia landscape on an Analyst/Industry conference call to be held on October 9 at 11 am.
10:18 EDTCMRXChimerix price target raised to $47 from $34 at Stifel
Subscribe for More Information
09:53 EDTCMRXChimerix price target raised to $41 from $37 at Piper Jaffray
Subscribe for More Information
09:20 EDTCMRXOn The Fly: Pre-market Movers
Subscribe for More Information
07:18 EDTMRKInfectious Diseases Society of America to hold a conference
ID Week 2014 is being held in Philadelphia on October 8-12.
06:36 EDTCMRXChimerix's Brincidofovir for adenovirus shows positive Phase 3 survival results
Chimerix announced preliminary data for its investigational antiviral brincidofovir showing improved survival for patients with adenovirus in the open-label pilot portion of the Phase 3 AdVise Trial. The preliminary survival analysis data showed a mortality rate of 35% vs. historic rates of up to 80% mortality in the first month after diagnosis. A majority of subjects also had suppression or clearance of adenovirus from the blood. There is currently no approved treatment for adenovirus. The safety and tolerability profile of brincidofovir in these initial subjects was similar to other studies of brincidofovir in immunocompromised patients with complicated medical issues, with only three subjects discontinuing due to adverse events.
October 7, 2014
13:28 EDTCMRXTekmira down 5% after report says Chimerix drug used on NBC journalist
Subscribe for More Information
13:13 EDTCMRXChimerix Ebola drug being used to treat U.S. patient in Nebraska, CNBC reports
Subscribe for More Information
October 6, 2014
13:59 EDTCMRXChimerix drug being used to treat U.S. Ebola patient in Texas, Reuters says
Brincidofovir, a drug developed by Chimerix, is being used to treat Thomas Duncan, a U.S. Ebola patient, at the Texas Health Presbyterian Hospital Dallas, Reuters said in a twitter post. Reference Link
09:25 EDTCMRXOn The Fly: Pre-market Movers
HIGHER: HP (HPQ), up 5% after confirming plans to separate into two companies... CareFusion (CFN), up 24% after Becton Dickinson (BDX) agreed to acquire the company for $58 per share in $12.2B deal. Becton Dickinson shares are up 7% following the news... Chimerix (CMRX), up 7% after announcing announced that brincidofovir has been provided for potential use in patients with Ebola Virus Disease... Conn's (CONN), up 6.5% after announcing that it is exploring strategic alternatives... TASER (TASR), up 5% after announces multiple orders of TASER Smart Weapons... Tableau (DATA), up 3.5% after upgraded at Morgan Stanley... Splunk (SPLK), up 3.9% after upgraded at Morgan Stanley... Unilife (UNIS), up 52% after signing a 15-year commercial supply agreement with Sanofi (SNY). LOWER: RadioShack (RSH), down 5% after confirming definitive agreements to restructure debt... Alcobra (ADHD), down 43% after announcing results from Phase III study of MDX in adult ADHD... Sunesis (SNSS), down 71% after announcing Phase 3 VALOR trial did not meet primary endpoint... H&R Block Bank (HRB), down 5% after deal with BofI (BOFI) not expected to get regulatory approval this year. Tekmira (TKMR), down 8% after downgraded at Leerink.
08:15 EDTCMRXChimerix up 9.4% after EIND applications for brincidofovir authorized by FDA
Subscribe for More Information
08:04 EDTCMRXChimerix announces EIND applications for brincidofovir authorized by FDA
Chimerix announced that brincidofovir has been provided for potential use in patients with Ebola Virus Disease. These requests were made by treating physicians. Emergency Investigational New Drug Applications, or EIND, were granted by the FDA. Chimerix is working closely with the FDA to finalize a clinical trial protocol early this week to assess the safety, tolerability, and efficacy of brincidofovir in patients who are confirmed to have an infection with the Ebola virus. Testing at the Viral Special Pathogens Branch of the CDC and the NIH revealed in vitro activity of brincidofovir against the Ebola virus that was similar to that seen in test tube assessments of brincidofovir against other viral diseases, such as adenovirus and smallpox. Additional tests of brincidofovir in in vivo models of Ebola virus infection are currently underway.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use